Advanced Nuclear Medicine Ingredients (ANMI) recently licensed a new Tc-99m radiopharmaceutical for use in detecting prostate cancer.
This new radiopharmaceutical is still in clinicals but, according to reports, is as sensitive as the Ga-68 labeled PSMS-11 analog used in PET imaging. This is very exciting for those in the SPECT community. Now Nuclear Medicine will have a SPECT alternative radiopharmaceutical for those without PET/CT capability. New applications are the lifeblood of Nuclear Medicine. This new Tc-99m radiopharmaceutical will open up prostate cancer detection and therapy monitoring for many more people around the globe.